Compared to SSTR, the role of CXCR4 has been studied more recently in lymphomas, especially in DLBCL, where CXCR4 upregulation has been shown to be associated with tumor cell dissemination, disease progression, and poor survival (14, 18, 22) and also with impaired response to rituximab treatment (23). This evidence concerns the gene CXCR4 and diffuse large B-cell lymphoma.